Paradigm Biopharmaceuticals (ASX:PAR) says it will submit its revised protocol for its long-awaited phase III trial for dodgy knees to the US Food & Drug Administration (FDA) by the end of the month – ...
Some results have been hidden because they may be inaccessible to you